The Rosen Law Firm, P.A. today announced that it has filed a class action lawsuit on behalf of investors who purchased the stock of Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) during the period between October 31, 2012 and October 18, 2013, inclusive seeking to recover damages for violations of the federal securities laws.
To join the Catalyst class action, visit the firm’s website at
, or call Phillip Kim, Esq. or Jonathan Horne, Esq., toll-free, at 866-767-3653; you may also email
for information on the class action. The lawsuit filed by the firm is pending in the U.S. District Court for the Southern District of Florida.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY CHOOSE TO DO NOTHING AT THIS POINT AND REMAIN AN ABSENT CLASS MEMBER.
The Complaint asserts violations of the federal securities laws against Catalyst and certain of its officers and directors for issuing materially false and misleading information about the Company. The Complaint asserts that Catalyst failed to disclose during the Class Period that one of its competitors has already been manufacturing a drug biologically equivalent to Firedapse–a drug Catalyst has claimed to be developing and marketing–and providing it to patients to treat Lambert-Eaton Myasthenic Syndrome free of charge, through a compassionate use program. The lawsuit asserts that the disclosure of this adverse information caused Catalyst’s share price to fall, damaging investors.
If you wish to serve as lead plaintiff, you must move the Court no later than December 24, 2013. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Jonathan Horne, Esq. of The Rosen Law Firm, toll-free, at 866-767-3653, or via e-mail at
. You may also visit the firm’s website at
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.